15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.

      Urologia internationalis
      Antineoplastic Agents, therapeutic use, Benzenesulfonates, Carcinoma, Renal Cell, drug therapy, secondary, surgery, Chemotherapy, Adjuvant, Humans, Kidney Neoplasms, pathology, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Invasiveness, Nephrectomy, Niacinamide, analogs & derivatives, Phenylurea Compounds, Protein Kinase Inhibitors, Pyridines, Tomography, X-Ray Computed, Treatment Outcome, Vena Cava, Inferior, Venous Thrombosis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A 53-year-old man presented with fever, 15 kg weight loss, ECOG performance status 0, and 12 × 9.5 cm renal tumor with an associated level II (near level III) tumor thrombus extending into the vena cava. We offered a presurgical targeted therapy to downsize the thrombus and primary tumor, which may reduce the extent of the surgery and operative risk. The patient accepted this approach with administration of sorafenib, resulting in a marked reduction of the primary renal tumor and 43% regression in tumor thrombus. Tumor shrinkage and regression of the thrombus allowed resection of the left kidney. Pathological findings revealed that part of the tumor was necrotic tissue. Two years after initiation of presurgical sorafenib therapy, the patient remains alive without evidence of disease progression. Copyright © 2011 S. Karger AG, Basel.

          Related collections

          Author and article information

          Comments

          Comment on this article